(April 6, 2020, Basel, Switzerland)

 

The global COVID-19 pandemic is a major threat to public health, forcing shutdowns that are bringing major economies to a halt. The race is on for biotechnology companies to produce therapeutic, prophylactic and diagnostics methods to SARS-CoV-2 infection. At deepCDR our team is ready to absorb the high influx of demand for our antibody engineering services. We are partnering with the world’s leading companies to rapidly bring their SARS-CoV-2 antibody leads into preclinical and clinical studies.

​

Antibody Optimization – Using our proprietary deep learning methods we are helping our customers increase the quality of their Antibody development programs by addressing manufacturing and immunogenic liabilities. For customers working on SARS-CoV-2, we are able to bring optimization projects down to half their original timeline from reception of candidate sequence(s) to optimized lead(s), i.e. within 8 weeks.

 

Patient Repertoire Analysis and Library Design – Using our proprietary deep sequencing and deep learning methods we are able to quickly provide our customers with patient repertoire analysis based on single or multiple patients. For customers working on SARS-CoV-2 we are able to bring Library build projects down to half their original timespan, i.e. within 4 weeks.

​

Antibody Design for Diagnostic Purposes – Our design workflow is also well adapted to customers working on the diagnostic end of SARS-CoV-2, in particular those developing Antibodies with improved specificity and affinity for ELISA-based assays.

​

Further to our services, deepCDR’s partner laboratory at the ETH Zurich has received special permission to open during the lockdown and conduct research related to SARS-CoV-2 with a full team. deepCDR’s SARS-CoV-2 research is complemented by a recent fast response grant to Prof. Sai Reddy’s laboratory from the European Union.

​

Please contact us to discuss your project needs and preferential pricing. andre.mercanzini@deepcdr.com